Literature DB >> 34850028

Infants Younger Than 6 Months Infected With SARS-CoV-2 Show the Highest Respiratory Viral Loads.

Valeria Ochoa1, Fernando Erra Díaz1, Ezequiel Ramirez1, María Clara Fentini1, Mauricio Carobene1, Jorge Geffner1, Lourdes Arruvito1, Federico Remes Lenicov1.   

Abstract

There is a paucity of reports on the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in infants, because most studies have grouped infants with older children. We analyzed the viral loads of 45318 SARS-CoV-2-positive nasopharyngeal swab samples obtained in Buenos Aires, Argentina. Infants younger than 6 months presented higher viral loads than any other age group. Children older than 6 months showed significantly lower viral loads, similar to those founds in adults. This observation raises new questions regarding the role of infants in the spreading of SARS-CoV-2 infection.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  19; 2; COVID; CoV; SARS; children; viral load

Mesh:

Year:  2022        PMID: 34850028      PMCID: PMC8690165          DOI: 10.1093/infdis/jiab577

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


Children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are usually asymptomatic or show a mild clinical course [1]. There is a paucity of reports specifically attending infants, because many studies have grouped them with older children, hiding potential differences between age subgroups [2-5]. Here, we compared the respiratory viral loads of younger infants with those of older children, making use of data from 175808 nasopharyngeal swabs processed between October 2020 and June 2021.

METHODS

Nasopharyngeal swab samples were collected at public and private health institutions from the city of Buenos Aires and the Greater Buenos Aires area, Argentina, from either symptomatic individuals or close contacts to a confirmed coronavirus disease 2019 (COVID-19) case. An independent Institutional Review Board (Fundación Huésped Bioethics Committee) waived the requirement of informed consent for the use of deidentified data in this study. Detection of SARS-CoV-2 was performed using SARS-CoV-2 Nucleic Acid Detection Kit (Transgen Biotech), which targets viral genes ORF1ab and N, and the human RPP30 gene as internal control. For the purpose of this study, samples were defined as positive when cycle threshold (Ct) values were below 36 for both ORF1ab and N genes. The reverse transcription polymerase chain reaction (RT-PCR) kit showed a dynamic range from Ct 15 to 36, with an efficiency of 89%, for ORF1ab amplification, as evaluated by plotting Ct versus log10 of serial dilutions of a low-Ct sample pool (r2 = 0.9932). The performance of the RT-PCR kit was controlled throughout the study by registering Ct values of positive controls in each run. When a positive control resulted in a Ct value outside of preestablished internal error limits, the run was repeated. Variant determination was carried out using the SARS-CoV-2 Extended ELITe MGB kit (ELITech Group). Briefly, a real-time RT-PCR was performed on RNA extracted from nasopharyngeal swab samples and then the following mutations were detected by melting curve analysis: L452Q, L452R, E484K, E484Q, and N501Y. Sanger sequencing of the S gene from selected samples confirmed the identity of the mutations. Statistical analysis was performed using nonparametric Kruskal-Wallis tests followed by Dunn post hoc test for multiple comparisons for group analysis of Ct values, and χ2 test to compare demographic data.

RESULTS

A total of 175808 samples were processed in the period between October 2020 and June 2021. We segmented our positive cohort (n = 45318) by 10-year intervals to compare viral loads between different age groups. The median value of ORF1ab Ct in the 0–9 years age group (n = 528) was significantly higher when compared to any other age group (median 27.19; interquartile range [IQR], 21.5–34.09; P value < .001; Figure 1A). The density plot showed a bimodal distribution of ORF1ab Ct values across all age groups, that is the distribution in the 0–9 years age group skewed to higher Cts, suggesting lower viral loads in the upper respiratory tract (Figure 1B). Next, we analyzed the Ct values within the 0–9 years age group by stratifying it in subgroups: 0–6 months, 7–12 months, 1–4 years, and 5–9 years. Notably, the 0–6 months age group (n = 46) displayed the lowest median value of ORF1a Ct (median, 20.77; IQR, 18.1–26.87) compared to any other age group, including adults (Figure 1C). The median Ct of the 0–6 months age group was between 6 and 10 cycles lower compared with either the 7–12 months (median, 30.12; IQR, 22.01–34.56; P value = .0001), 1–4 years (median, 30.46; IQR, 22.34–34.69; P value < .0001), or the 5–9 years age group (median, 26.58; IQR, 22.34–33.8; P value = .0001).
Figure 1.

ORF1a cycle threshold (Ct) values across age groups. A, The total 45318 positive samples segmented by 10-year age intervals; ∗∗∗ 0–9 years versus other groups, P < .001. B, Density plot showing Ct value distribution; colors correspond to groups in (A). C, Ct values from infant and children subgroups; ∗∗∗ 0–6 months versus any other age group, P < .001. In the violin plots, boxes depict the IQR, the horizontal line the median and the whiskers the 95% CI.

ORF1a cycle threshold (Ct) values across age groups. A, The total 45318 positive samples segmented by 10-year age intervals; ∗∗∗ 0–9 years versus other groups, P < .001. B, Density plot showing Ct value distribution; colors correspond to groups in (A). C, Ct values from infant and children subgroups; ∗∗∗ 0–6 months versus any other age group, P < .001. In the violin plots, boxes depict the IQR, the horizontal line the median and the whiskers the 95% CI. These results could not be explained by known confounders of viral load determination. First, there were no differences among age groups in the median Ct values for the internal control gene (RPP30) or in the time between symptom onset and sample collection (Table 1). Second, there have been studies on the possible association between symptomatic infection and higher viral loads, with contrasting findings [6-8]. In this regard, it should be emphasized that in our cohort the frequency of symptomatic patients was similar across all age groups (Table 1). Third, another potential confounder when analyzing viral loads across time is the displacement of circulating variants by the Delta variant, which is characterized by high viral shedding. By the end of our study, in June 2021, there was only 1 reported case (an inbound traveler) of Delta variant in Argentina, according to genomic surveillance public data [9]. Community circulation of the Delta variant in the Buenos Aires area was first demonstrated in samples obtained during August 2021 [10]. Furthermore, we retrospectively assessed 66 samples obtained between April and June (the final months of our study) to determine the presence of variant-associated mutations in the S gene. All age groups were represented in the sampling (range, 0–87 years old). We found 34 samples (52%) carrying mutations E448K and N501Y (compatible with Gamma variant of concern) and 30 (45%) samples carrying mutation L452Q (compatible with the Lambda variant of interest). Two other samples presented either no mutation or only the N501Y mutation. We did not find the Delta-associated L452R mutation in any of the samples, further indicating that our data distribution was not skewed by Delta variant introduction. Finally, vaccination status could not be considered as a confounder factor, because by the end of our study only 6.72% of the general population in the Buenos Aires area had been vaccinated, and at this time vaccination was concentrated in health care workers and the elderly and did not include children [11].
Table 1.

Demographic and Sample Characteristics of 528 Children and Infants Younger Than 10 Years Who Tested Positive for SARS-CoV-2

Characteristic Group 1 0–6 mo (n = 46) Group 2 7–12 mo (n = 40) Group 3 1–4 y (n = 167) Group 4 5–9 y (n = 275)
Sexa
 Female, No. (%)21 (46)21 (53)83 (50)141 (51)
 Male, No. (%)25 (54)19 (48)84 (50)134 (49)
Reported symptomsa
 Symptomatic, No. (%)28 (61)28 (70)101 (60)165 (60)
 No reported symptoms, No. (%)18 (39)12 (30)66 (40)110 (40)
Time from symptom onset to sample collection, d, median (IQR)2 (1–3)3 (2–4)3 (2–4)3 (2–4)
PCR internal control RPP30 Ct, mean (SD)b26.36 (2.03)25.79 (1.6)26.31 (2.21)26.60 (2.1)

Abbreviations: Ct, cycle threshold value; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

χ2analysis showed no significant differences among the analyzed groups (P value > .05).

Krustall-Wallis analysis was performed. Dunn multiple comparisons test showed no significant differences. Group 1 vs group 2, adjusted P value = .81; group 1 vs group 3/group 4, adjusted P value > .99.

Demographic and Sample Characteristics of 528 Children and Infants Younger Than 10 Years Who Tested Positive for SARS-CoV-2 Abbreviations: Ct, cycle threshold value; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. χ2analysis showed no significant differences among the analyzed groups (P value > .05). Krustall-Wallis analysis was performed. Dunn multiple comparisons test showed no significant differences. Group 1 vs group 2, adjusted P value = .81; group 1 vs group 3/group 4, adjusted P value > .99.

DISCUSSION

While it is clear that SARS-CoV-2 infection in children is mostly mild and often asymptomatic, its contribution to spreading of the infection has not been well defined [12, 13]. In this regard, it should be noted that most previous studies have analyzed pediatric COVID-19, considering children as a homogeneous population. We found that infants younger than 6 months showed higher viral loads than any other age group. Our observations are partially consistent with a previous study, which reported that infants younger than 12 months with symptomatic COVID-19 had higher nasopharyngeal viral loads compared with older children and adolescents [7]. Here, by studying a larger cohort of patients, we found that SARS-CoV-2–infected children younger than 6 months, either symptomatic or asymptomatic, show the highest viral loads. In contrast, our data indicate that children older than 7 months display lower viral loads compared to those found in adults. These findings are consistent with recent studies directed at analyzing the role of children in SARS-CoV-2 transmission. A large epidemiological study by Paul et al found that children aged 0 to 3 years showed the highest probability of transmitting SARS-CoV-2 to household contacts when compared to older children [12]. Previously, a study from Spain had found a similar result for a group aged 0 to 2 years [14]. Our results suggest that higher viral loads in the infant population could be a contributing factor, explaining increased transmission by this age group compared to older children. Our results reinforce the notion that there is not a direct correlation between viral load and disease severity. In our cohort, younger infants (0–6 months old) showed Ct values between 6 and 10 cycles lower than other children, while they were reported to have equal or even a lower proportion of symptomatic infections. Our observations are in agreement with those presented by Zachariah et al, which showed less-severe presentation but higher viral loads in infants [7]. One limitation of our study is the use of Ct values as a proxy for viral load. While Ct values are inversely correlated to the logarithm of viral load, the actual conversion depends on the PCR design and efficiency. Thus, raw Ct values reported in this study cannot be directly compared to Ct values obtained under different assay conditions. In conclusion, we found that children younger than 6 months display higher SARS-CoV-2 viral loads compared to all other age groups. Whether this reflects a lower ability to control SARS-CoV-2 replication in the upper respiratory tract remains to be established.
  2 in total

1.  SARS-CoV-2 infections in infants in Haiti 2020-2021; evidence from a seroepidemiological cohort.

Authors:  Rigan Louis; Ruiyu Pu; Tracey D Logan; Luke Trimmer-Smith; Richard Chamblain; Adriana Gallagher; Valery Madsen Beau De Rochars; Eric Nelson; Derek A T Cummings; Maureen T Long; J Glenn Morris
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

2.  Upper airway gene expression shows a more robust adaptive immune response to SARS-CoV-2 in children.

Authors:  Eran Mick; Alexandra Tsitsiklis; Natasha Spottiswoode; Saharai Caldera; Paula Hayakawa Serpa; Angela M Detweiler; Norma Neff; Angela Oliveira Pisco; Lucy M Li; Hanna Retallack; Kalani Ratnasiri; Kayla M Williamson; Victoria Soesanto; Eric A F Simões; Christiana Smith; Lisa Abuogi; Amy Kistler; Brandie D Wagner; Joseph L DeRisi; Lilliam Ambroggio; Peter M Mourani; Charles R Langelier
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.